障碍或病症的焦虑,或者患有创伤后应激性障碍(stress disorder)的受治疗者的方法,包含给药予受治疗者治疗有效量的(a)A2D配体和(b)5-羟色胺重摄取抑制剂(SSRI)或者(c)去甲肾上腺素重摄取抑制剂(SNRI)或者(a)、(b)和(c)的联用药物(combination)。
Major depressive disorder (MDD) is both highly prevalent and debilitating. MDD affects over 320 million people worldwide, is the main precursor of suicide, and is the leading cause of disability globally, with profound impacts on daily life, work, and relationships1,2,3,4. The remission rate ...